Mark Angelino
Stealth at newco
Mark Angelino
Stealth at newco
Greater Boston
Overview
Work Experience
…
2023 - Current
Innovation and Technology Advisory group (ITAG)
2022
CCRM is a not-for-profit, public-private consortium supporting the development of foundational technologies that accelerate the commercialization of cell and gene therapies, and regenerative medicine technologies.
Independent Board Member
2021
Venture Partner
2021 - 2023
- CGT: company creation (2), series A (Cargo Tx)
Chief Operating Officer and founder
2016 - 2021
SVP, Pharmaceutical Sciences
2012 - 2016
- Member of Leadership Team - Responsible for development, manufacturing, and operations; franchise lead for rare diseases - Skysona, Zynteglo, Abecma, and Lyfgenia
Sr. Director, Research and Development; Site Head-Cambridge
2008 - 2012
- Lead all R&D (res., cmc, dmpk, tox, quality) and Operation functions for the Cambridge, MA site - Transferred with the acquisition of Archemix hemophilia assets - Led diligence for gene therapy assets (resulted in Chatham Tx acquisition)
Senior Director, Process Development and Manufacturing
2007 - 2008
- Managed validation and regulatory responses for enoxaparin (Lovenox) ANDA approval. - Lead dev. & manufacturing for glatiramir acetate (Copaxone) ANDA. Primary author on ANDA.
Associate Director, Process Development
2002 - 2006